NANO Nuclear Energy and Tillman Global Holdings have signed a strategic framework to collaborate on deploying over 2 gigawatts of advanced nuclear power by the mid-2030s, targeting 6 gigawatts by 2040, to support Tillman's AI industrial zones in the US. This partnership aims to integrate NANO's modular KRONOS MMR nuclear reactors with Tillman's data center infrastructure, providing reliable, scalable baseload power for AI and hyperscale computing needs. The deal includes milestone-based stock warrants and potential equity participation, with plans to expand internationally. This collaboration addresses growing power demands for AI infrastructure and represents a significant commercialization step for NANO Nuclear's technology.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
